Complications of Video-Assisted Thoracoscopic Lung Biopsy in Patients with Interstitial Lung Disease
|
|
- Matthew Benson
- 6 years ago
- Views:
Transcription
1 Complications of Video-Assisted Thoracoscopic Lung Biopsy in Patients with Interstitial Lung Disease Mary Elizabeth Kreider, MD, MS, John Hansen-Flaschen, MD, Nadia N. Ahmad, MD, Milton D. Rossman, MD, Larry R. Kaiser, MD, John C. Kucharczuk, MD, and Joseph B. Shrager, MD Pulmonary, Allergy and Critical Care Division, and Thoracic Surgery Division, University of Pennsylvania School of Medicine; and the Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Background. Current guidelines recommend surgical lung biopsy for diagnosis of interstitial lung diseases (ILDs) in selected patients. To shed light on the risk benefit ratio for this recommendation, we examined the morbidity and mortality associated with video-assisted thoracoscopic surgical (VATS) lung biopsy in a group of outpatients. Methods. A retrospective cohort study was conducted of 68 consecutive ambulatory patients with radiographically apparent interstitial lung disease (ILD) referred for VATS biopsy during a 6-year period. Incidence of postoperative mortality, prolonged air leaks, pneumonias, and re-admissions were calculated. Risk factors for complications of surgery were examined. Results. Three deaths occurred within 60 days after biopsy for a mortality rate of 4.4% (95% confidence interval [CI], 1% to 12%), and 19.1% (95% CI, 11% to 31%) experienced one or more complications of surgery. Risk factors for morbidity included preoperative dependence on oxygen therapy and pulmonary hypertension. The three patients who died had usual interstitial pneumonia on their biopsy specimen and were reintubated postoperatively for acute lung injury. Aggregation of articles published over the past 10 years reporting on surgical lung biopsy for the diagnosis of ILD yielded a postoperative mortality rate of 2% to 4.5%. Conclusions. VATS lung biopsy for diagnosis of ILD, even in ambulatory patients, is not an entirely benign procedure. Biopsy rarely may trigger an acute exacerbation of usual interstitial pneumonitis. The risk of postoperative complications appears to be greatest in those dependent on oxygen and those who have pulmonary hypertension. This information may be used in weighing the risk benefit ratio of biopsy in individual patients. (Ann Thorac Surg 2007;83:1140 5) 2007 by The Society of Thoracic Surgeons In 2002, the American Thoracic Society (ATS) and the European Respiratory Society released a joint statement on the classification and diagnosis of the idiopathic interstitial pneumonias (IIPs) [1]. The recommended scheme classification relies heavily on lung pathology: Because the histological patterns seen by pathologists usually allow for better separation of these entities than the imaging patterns seen by radiologists, these histological patterns provide the primary basis for the various categories of the IIPs and serve as the foundation of the classification... In the absence of contraindications, surgical lung biopsy is advised in patients with suspected IIP who do not show the classic clinical and HRCT (high resolution chest CAT scan) picture of IPF/UIP. Accepted for publication Oct 2, Address correspondence to Dr Kreider, 826 W. Gates, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104; kreiderm@mail.med.upenn.edu. Although the benefits of surgical lung biopsy are well defined in the statement, the risks and contraindications are not. In the current study, we performed a retrospective cohort analysis of all outpatients who underwent videoassisted thoracoscopic surgical (VATS) lung biopsy to establish a specific diagnosis after presentation with clinically and radiographically apparent interstitial lung disease (ILD). Our objectives were (1) to determine the incidence of major postoperative complications for this diagnostic procedure, including death, pneumonia, prolonged air leaks, prolonged hospital stay, and hospital readmission; and (2) to compare the clinical characteristics of patients in whom these complications develop with the characteristics of those who tolerate the procedure to help determine if there is a subgroup of patients in whom the risks outweigh the potential benefits. Patients and Methods Study Design We performed a retrospective cohort study of consecutive outpatients who underwent VATS lung biopsy for diagnosis of an ILD between January of 1998 and July of 2004 at The Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. During this study period, no open lung biopsy procedures were performed on outpatients referred for diagnosis of an ILD. The study protocol 2007 by The Society of Thoracic Surgeons /07/$32.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg KREIDER ET AL 2007;83: COMPLICATIONS OF VATS LUNG BIOPSY FOR ILD 1141 Table 1. Study Population (n 68) Characteristic % (n) or (range) Age (mean, years) 58 (38 84) Gender Male 44% (30) Female 56% (38) Smoking status Never 43% (27) Former 50% (34) Current 7% (5) Pre-op PFTs (mean % predicted) FVC 66.9% (18 110) FEV % (37 108) TLC 72.7% (32 106) Dlco 50.9% (19 113) Pre-op O 2 dependence 33% (22) Pre-op pulmonary HTN (18 tested) 56% (10) Subsequent pathologic diagnoses Usual IP 34% (23) Sarcoidosis 9% (6) Honeycomb lung 9% (6) Chronic hypersensitivity 7.5% (5) Nonspecific IP 6% (4) Desquamative IP 4.5% (3) Respiratory bronchiolitis-ild Normal lung 3% (2) Acute IP 1.5% (1) Bronchiolitis 1.5% (1) Nonclassifiable 23.5% (16) Dlco diffusing capacity of the lung for carbon monoxide; FEV 1 forced expiratory volume in 1 second; FVC forced vital capacity; HTN hypertension; ILD interstitial lung disease; IP interstitial pneumonia; PFTs pulmonary function testing; TLC total lung capacity. was reviewed and approved by the Institutional Review Board at the University of Pennsylvania in December 2004 and 2005, and an exemption for the requirement for informed consent was granted. In addition, we performed a literature review and meta-analysis separately from our retrospective patient cohort. We searched Medline for English language articles published from 1995 through 2005 using the MESH search terms biopsy or video-assisted thoracic surgery and either lung diseases, or interstitial or pulmonary fibrosis. From 869 articles retrieved in this initial screen, two authors (MEK and JHF) identified original research articles on cohorts of more than 10 adults who underwent surgical lung biopsy for diagnosis of a subacute or chronic, diffuse ILD. The references cited in these articles were reviewed to find additional studies. Twenty-two articles were identified and abstracted to calculate a composite mortality estimate with a 95% confidence interval (CI). Outcome Definitions The primary outcome for the cohort study was 60-day postoperative mortality from any cause. Secondary outcomes included prolonged length of stay (defined as 5 days), readmission within 30 days of surgery, pneumonia, prolonged air leak (chest tube in place for 5 days), and any mechanical ventilation postoperatively. Finally, a composite outcome was created, termed morbidity, which was defined as any one or more of the primary or secondary outcome measures. Subjects were only counted once if they met more than one outcome. This composite outcome was used for risk factor analysis to increase the power to detect associations. Candidate Risk Factors Information on candidate risk factors abstracted from all subjects charts included preoperative pulmonary function test results, a preoperative prescription for longterm oxygen therapy, pathologic diagnosis, presence or absence of pulmonary hypertension, which was defined as pulmonary artery systolic pressure (PASP) of 40 mm Hg or more as estimated by echocardiogram or measured on right heart catheterization; race, gender, age at the time of biopsy, current pharmacologic therapy for ILD, and smoking status. Analysis The incidence of all outcomes was calculated along with their 95% CIs. To identify potential risk factors for morbidity, we performed univariate analysis with contingency tables for discrete variables and logistic regression for continuous data. All risk factors with p 0.2 in univariate analysis were then included in a multivariate logistic regression. Colinearity was assessed for, and if found, the less predictive of the two risk factors was removed from the final model. Results Study Population The cohort of 68 patients included in this report is described in Table 1. The subjects had an average age of 58 years (range, 38 to 84 years), 56% were women, and 73% were white. Fifty percent were former smokers. Most had mild-to-moderate pulmonary functional impairment as determined by pulmonary function testing. Thirteen patients (19%) were taking oral corticosteroids, another 13 (19%) were taking inhaled corticosteroids at the time of biopsy, and 1 patient was taking methotrexate preop- Table 2. Incidence of Outcomes Outcome Incidence (n) 95% CI 1. Mortality ( 60 days) 4.4% (3) 1 12% 2. Prolonged air leak ( 5 days) 4.4% (3) 1 12% 3. Post-op pneumonia 2.9% (2) % 4. Hospital readmission ( 1 month) 10.7% (7) 4 21% 5. Prolonged hospital stay ( 5 days) 4.4% (3) 1 12% 6. Mechanical ventilation post-op 5.9% (4) 2 14% Composite-any of the outcomes % (13) 11 31% CI confidence interval.
3 1142 KREIDER ET AL Ann Thorac Surg COMPLICATIONS OF VATS LUNG BIOPSY FOR ILD 2007;83: Table 3. Clinical Characteristics of the Subjects Who Died Patient FVC % DLCO % Supplemental O2? PASP Path dx Intubated on POD # Died on POD # 58 y.o. WM Yes at 4 LPM N/A UIP y.o. WF Yes at 3 LPM 45 UIP y.o. WM Yes at 2 LPM 46 UIP 2 4 Dlco diffusing capacity of the lung for carbon monoxide; FVC forced vital capacity; LPM liters per minute; PASP pulmonary artery systolic pressure; Path dx pathological diagnosis; POD post operative day; UIP usal interstitial pneumonitis; WF white female; WM white male. eratively. These subjects were considered to have failed empiric therapy and required a diagnosis for further therapeutic intervention. All subjects had undergone preoperative computed tomography (CT) scans that were not considered diagnostic of a specific ILD. No patients in the cohort had human immunodeficiency virus infection or active cancer. Adverse Outcomes Surgical morbidity and mortality are presented in Table 2. Three deaths occurred within 60 days after biopsy for an incidence of 4.4% (95% CI, 1% to 12%). The most frequent major complications were a need for hospital readmission in 10.7% (95% CI, 4% to 21%) and mechanical ventilation postoperatively in 5.9% (95% CI, 2% to 14%). The reasons for readmission included pneumothorax in 4 patients, hematoma at incision site in 1, and respiratory failure in 2. Altogether, 19.1% of patients experienced one or more of the recorded complications (95% CI, 11% to 31%). Description of Mortality The clinical characteristics of the 3 patients who died after VATS lung biopsy are summarized in Table 3. All three were extubated immediately after surgery, but then progressive hypoxemia developed that required reintubation 1 to 8 days after biopsy. Histologic examination of the VATS lung biopsy specimens from these 3 patients revealed usual interstitial pneumonitis by standard criteria [2]. Shortly after biopsy, new ground-glass opacities were observed on chest CT in all 3 patients. Bronchoscopy revealed no evidence of acute infection. Congestive heart failure and pulmonary embolism were excluded by echocardiogram and CT angiogram. All 3 patients were treated with intravenous antibiotics and glucocorticoids. Table 4. Multivariate Analysis of Risk Factors for Major Morbidity Risk factor OR (95% CI) p Value O2 therapy pre-op 20.9 ( ) 0.02 TLC % pred 0.82 ( ) 0.05 DLCO % pred 1.00 ( ) 0.92 UIP on biopsy 1.90 ( ) 0.51 Age biopsy 1.01 ( ) 0.91 CI confidence interval; Dlco diffusing capacity of the lung for carbon monoxide; OR odds ratio; TLC total lung capacity; UIP usual interstitial pneumonitis. No clinical improvement occurred, and the patients died at 4, 20, and 43 days after biopsy. Postmortem examinations were performed on two patients. Both had findings of diffuse alveolar damage on a background of usual interstitial pneumonitis, consistent with an acute exacerbation of usual interstitial pneumonitis [3]. There were too few deaths to compare characteristics of survivors and nonsurvivors. Risk Factor Analysis The results of multivariate risk factor analysis are presented in Table 4. Patients who required oxygen therapy preoperatively had an elevated odds ratio (OR) of developing major morbidity of 20.9 compared with those without oxygen (95% CI, 1.67 to 261.6, p 0.02). There was also a suggestion that people with more severely impaired percentage of total lung capacity (TLC%) predicted had higher odds of poor outcome (OR, 0.82; 95% CI, 0.68 to 1.00; p 0.05). In our cohort, only 18 patients underwent testing for pulmonary hypertension, either by echocardiogram in 17 or right heart catheterization in 1. Of these, 8 had a PASP of greater than 40, and 4 patients within this subgroup had a complication for a 50% morbidity incidence (95% CI, 15% to 85%) compared with no morbidity in those without pulmonary hypertension (p 0.01 comparing proportion). Two of the three patients who died had documented pulmonary hypertension; the third was not studied. Comment Our study demonstrates a 60-day mortality rate of 4.4% and a morbidity rate of 19% in 68 consecutive outpatients undergoing VATS lung biopsy for diagnosis of an ILD at one university hospital. We find further that preoperative oxygen use, lower TLC%, and a PASP greater than 40 were statistically associated with the development of morbidity. Elevated pulmonary artery pressure was present in two thirds of those who died, but the lack of this having been measured preoperatively in all patients prevents us from drawing a firm conclusion about the relationship between pulmonary artery pressures and postoperative mortality. One recently published study is comparable to ours in research design. Lettieri and colleagues [4] retrospectively examined a cohort of 83 patients who underwent VATS lung biopsy at Walter Reed Army Medical Center for diagnosis of ILD. In contrast to our cohort, theirs
4 Ann Thorac Surg KREIDER ET AL 2007;83: COMPLICATIONS OF VATS LUNG BIOPSY FOR ILD 1143 included 8 patients (9.6%) who required mechanical ventilation for respiratory failure immediately before biopsy. They reported mortality of 4.8% at 30 days and 6.0% at 90 days for their study patients. Overall, 12 patients (14%) experienced a major complication of surgery or died within 90 days. Notably, 3 of the 8 patients who required mechanical ventilation before biopsy died within 90 days after biopsy. Excluding these patients, the postoperative death rate for the remaining 75 patients was 2.7%. It may be possible to limit the risk of complications associated with surgical lung biopsy for the diagnosis of ILD by identification and careful consideration of preoperative risk factors for adverse surgical outcomes. In our cohort of 68 patients, we found that preoperative dependence on long-term oxygen therapy, lower TLC, and pulmonary hypertension as measured by echocardiogram predicted an adverse outcome. Carrillo and colleagues [9] identified multiple comorbidities, a greater score on the ATS dyspnea scale, a higher respiratory rate, a lower Pao 2, higher Paco 2, and a Paco 2 /Pao 2 index of 0.72 or higher as risk factors for mortality in their case control analysis. Preoperative ventilator dependence and an immunocompromised status were the only predictors of mortality in the Lettieri and colleagues analysis [4]. In the review of the experience at the Mayo Clinic with lung biopsy for usual interstitial pneumonitis, Utz and colleagues [5] found that a diffusing capacity of the lung for carbon monoxide of less than 35% predicted and idiopathic usual interstitial pneumonitis (versus usual interstitial pneumonitis associated with collagen vascular disease) were predictors of mortality. All in all, ILD patients with more severe lung disease appear to be at greater risk for complications of surgical lung biopsy. Our findings emphasize of the significance of preoperative pulmonary hypertension. Efforts to reduce the mortality associated with the diagnosis of ILD by surgical lung biopsy may also benefit from a more complete understanding of the causes of death in these patients. Within 8 days after biopsy, the 3 patients who died postoperatively in our series required reintubation for respiratory distress and new widespread pulmonary infiltrates that could not be attributed to known causes of acute lung injury such as aspiration or sepsis. All were found to have usual interstitial pneumonitis on the surgical lung biopsy specimen. A postmortem examination was performed on 2 of the 3 patients and found extensive diffuse alveolar damage that was not apparent at the time of the surgical lung biopsy. These findings suggest that VATS lung biopsy or some unrecognized perioperative event that may occur in association with VATS lung biopsy triggered a fatal episode of acute lung injury in 3 of our patients who had underlying usual interstitial pneumonitis. Several published studies have drawn attention recently to unexpected, apparently irreversible episodes of accelerated decline in lung function experienced by patients with idiopathic pulmonary fibrosis (IPF) [3, 6, 7]. These episodes are characterized by development of widespread ground-glass opacities on chest CT images and by the postmortem finding of diffuse alveolar damage superimposed on usual interstitial pneumonitis [6]. Because many such episodes have occurred without an identifiable precipitating cause, the phenomenon has been attributed to an acute exacerbation of IPF. The 3 patients who died in our study cohort, the 4 who died in the study by Tiitto and colleagues [8], and 2 patients described by Kim and colleagues [6] all experienced an acute, fatal deterioration in lung function that was similar clinically, radiographically, and pathologically to that reported for acute exacerbations of IPF. Whether surgical lung biopsy sometimes triggers an acute exacerbation of underlying IPF or sometimes precipitates an etiologically distinct form of acute lung injury superimposed on preexisting IPF is unknown and remains to be determined. There are several limitations to our cohort study. Because our analysis was performed retrospectively, every subject did not receive the same evaluation before biopsy, and thus, some risk factor data are missing. This was especially true for pulmonary hypertension, where only a fraction of subjects were screened. In addition, the screening was largely done with echocardiography, which may be a relatively inaccurate measure of pulmonary hypertension. Nonetheless, the observation that those with a suggestion of pulmonary hypertension did far more poorly than those documented not to have pulmonary hypertension is of significant concern and should be strongly considered in those being evaluated for lung biopsy. Another potential problem of a retrospective cohort study is loss to follow-up. Only 1 subject in our cohort was lost for mortality information, and this was completed with the Social Security death index; therefore, our data on short-term outcomes were fairly complete. However, other longer-term outcomes such as persistent worsening lung function postoperatively could not be examined because they were not routinely monitored. In addition, the study was performed on patients who underwent surgery performed by a four-physician academic thoracic surgery practice and thus may not be representative of the patient populations and clinical practices of other centers. The number of subjects examined limited our ability to examine risk factors associated with poor outcomes. To place our results in the context of previously reported studies of complications of lung biopsy for ILD, we performed a literature search and meta-analysis. Using the search strategy described in the Methods section, we identified 22 studies published in English during the past 10 years in addition to ours that reported postoperative mortality after surgical lung biopsy for the diagnosis of an ILD [4, 5, 8 29]. A composite postoperative mortality of rate 4.5% (95% CI, 3.7% to 5.5%) was calculated for the 2223 patients included in all 22 previously published studies plus our own. Studies published from 2001 through 2005 reported rates of mortality that were not significantly different from those published between 1995 and A significantly higher mortality
5 1144 KREIDER ET AL Ann Thorac Surg COMPLICATIONS OF VATS LUNG BIOPSY FOR ILD 2007;83: rate of 47.3% was seen in patients requiring preoperative ventilation compared with 2.2% in those free from ventilation (p 0.001). Despite the clear limitations of even systematic literature reviews like this, several observations from this study warrant consideration. The review confirms our finding that morbidity and mortality associated with surgical lung biopsy for diagnosis of ILD disease is certainly not nil. This may be due to progression of significant disease in an already ill population, or alternatively, it is possible that the surgery itself, or associated procedures such as general anesthesia and positive pressure ventilation, can result in an accelerated decline. Importantly, surgical lung biopsy clearly may trigger an exacerbation of IPF or a closely related phenomenon of unexplained acute lung injury in some patients who have this disease. In conclusion, the potential benefits of diagnostic surgical lung biopsy must be considered against the risks of the procedure as detailed in this report, especially for patients with more severe cardiovascular-pulmonary functional impairment (specifically, preoperative oxygen use and lower TLC). Consideration should also be given to screening potential surgical subjects for the presence of pulmonary hypertension, as patients with significantly elevated PASP appear also to be at considerably higher risk. The risks of biopsy do not appear to be reduced by a VATS approach. Rapid pulmonary deterioration after biopsy in most cases is due to acute lung injury and not infection. Awareness of the complications of surgical lung biopsy should stimulate interest in developing alternatives to surgical lung biopsy for differentiating among the ILDs. References 1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165: Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157: Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22: Lettieri CJ, Veerappan GR, Helman DL, Mulligan CR, Shorr AF. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005;127: Utz JP, Ryu JH, Douglas WW, et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001;17: Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27: Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142: Tiitto L, Heiskanen U, Bloigu R, et al. Thoracoscopic lung biopsy is a safe procedure in diagnosing usual interstitial pneumonia. Chest 2005;128: Carrillo G, Estrada A, Pedroza J, et al. Preoperative risk factors associated with mortality in lung biopsy patients with interstitial lung disease. J Invest Surg 2005;18: Ooi A, Iyenger S, Ferguson J, Ritchie AJ. VATS lung biopsy in suspected, diffuse interstitial lung disease provides diagnosis, and alters management strategies. Heart Lung Circ 2005;14: Lee YC, Wu CT, Hsu HH, Huang PM, Chang YL. Surgical lung biopsy for diffuse pulmonary disease: experience of 196 patients. J Thorac Cardiovasc Surg 2005;129: Yamaguchi M, Yoshino I, Suemitsu R, et al. Elective videoassisted thoracoscopic lung biopsy for interstitial lung disease. Asian Cardiovasc Thorac Ann 2004;12: Ayed AK. Video-assisted thoracoscopic lung biopsy in the diagnosis of diffuse interstitial lung disease. A prospective study. J Cardiovasc Surg (Torino) 2003;44: Ayed AK, Raghunathan R. Thoracoscopy versus open lung biopsy in the diagnosis of interstitial lung disease: a randomised controlled trial. J R Coll Surg Edinb 2000;45: Chang AC, Yee J, Orringer MB, Iannettoni MD. Diagnostic thoracoscopic lung biopsy: an outpatient experience. Ann Thorac Surg 2002;74:1942 6; discussion Riha RL, Duhig EE, Clarke BE, Steele RH, Slaughter RE, Zimmerman PV. Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia. Eur Respir J 2002;19: Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166: Qureshi RA, Soorae AA. Efficacy of thoracoscopic lung biopsy in interstitial lung diseases: comparison with open lung biopsy. J Coll Physicians Surg Pak 2003;13: Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164: Blewett CJ, Bennett WF, Miller JD, Urschel JD. Open lung biopsy as an outpatient procedure. Ann Thorac Surg 2001; 71: Miller JD, Urschel JD, Cox G, et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann Thorac Surg 2000;70: Temes RT, Joste NE, Qualls CR, et al. Lung biopsy: is it necessary? J Thorac Cardiovasc Surg 1999;118: Rena O, Casadio C, Leo F, et al. Videothoracoscopic lung biopsy in the diagnosis of interstitial lung disease. Eur J Cardiothorac Surg 1999;16: Neuhaus SJ, Matar KS. The efficacy of open lung biopsy. Aust N Z J Surg 1997;67: Mouroux J, Clary-Meinesz C, Padovani B, et al. Efficacy and safety of videothoracoscopic lung biopsy in the diagnosis of interstitial lung disease. Eur J Cardiothorac Surg 1997;11: 22 4, Zegdi R, Azorin J, Tremblay B, Destable MD, Lajos PS, Valeyre D. Videothoracoscopic lung biopsy in diffuse infiltrative lung diseases: a 5-year surgical experience. Ann Thorac Surg 1998;66: Ravini M, Ferraro G, Barbieri B, Colombo P, Rizzato G. Changing strategies of lung biopsies in diffuse lung diseases: the impact of video-assisted thoracoscopy. Eur Respir J 1998;11: Deshmukh SP, Krasna MJ, McLaughlin JS. Video assisted thoracoscopic biopsy for interstitial lung disease. Int Surg 1996;81: Krasna MJ, White CS, Aisner SC, Templeton PA, McLaughlin JS. The role of thoracoscopy in the diagnosis of interstitial lung disease. Ann Thorac Surg 1995;59:
Interstitial lung disease (ILD) is a group of diseases with
Diagnostic Surgical Lung Biopsies for Suspected Interstitial Lung Diseases: A Retrospective Study Martin I. Sigurdsson, MD, Helgi J. Isaksson, MD, Gunnar Gudmundsson, MD, PhD, and Tomas Gudbjartsson, MD,
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationEfficacy and safety of surgical lung biopsy for interstitial disease. Experience of 161 consecutive patients from a single institution in Italy
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; 251-258 Mattioli 1885 Efficacy and safety of surgical lung biopsy for interstitial disease. Experience of
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationMethods ROLE OF OPEN LUNG BIOPSY IN PATIENTS WITH DIFFUSE LUNG INFILTRATES AND ACUTE RESPIRATORY FAILURE
ROLE OF OPEN LUNG BIOPSY IN PATIENTS WITH DIFFUSE LUNG INFILTRATES AND ACUTE RESPIRATORY FAILURE Li-Hui Soh, Chih-Feng Chian, Wen-Lin Su, Horng-Chin Yan, Wann-Cherng Perng, and Chin-Pyng Wu Background
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationImaging: how to recognise idiopathic pulmonary fibrosis
REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,
More informationJune 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationSurvival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Eur Respir J 2002; 19: 1114 1118 DOI: 10.1183/09031936.02.00244002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Survival of patients with
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationInitial presentation of idiopathic pulmonary fibrosis as an acute exacerbation
Respiratory Medicine CME (2008) 1, 43 47 respiratory MEDICINE CME CASE REPORT Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation Krishna M. Sundar a,b,, Dixie L. Harris a a
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationProtocol. Lung Volume Reduction Surgery for Severe Emphysema
Protocol Lung Volume Reduction Surgery for Severe Emphysema (70171) Medical Benefit Effective Date: 01/01/12 Next Review Date: 09/14 Preauthorization Yes Review Dates: 02/07, 01/08, 11/08, 09/09, 09/10,
More informationNonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis
Original Article Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Xia Li 1, Chang Chen 2, Jinfu Xu 1, Jinming Liu 1, Xianghua
More informationI diopathic pulmonary fibrosis (IPF) is the most common
1091 INTERSTITIAL LUNG DISEASE Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia L Tiitto, R Bloigu, U Heiskanen, P Pääkkö, V
More informationIdiopathic pulmonary fibrosis (IPF) is a
Eur Respir J 2011; 38: 176 183 DOI: 10.1183/09031936.00114010 CopyrightßERS 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema S.L. Schmidt*,
More informationThe Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationDiffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious
Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationIn idiopathic pulmonary fibrosis (IPF) and
Eur Respir J 2010; 35: 830 835 DOI: 10.1183/09031936.00155108 CopyrightßERS Journals Ltd 2010 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
More informationOntario s Referral and Listing Criteria for Adult Lung Transplantation
Ontario s Referral and Listing Criteria for Adult Lung Transplantation Version 3.0 Trillium Gift of Life Network Adult Lung Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationUSEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT
More informationInfluence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern
ORIGINAL ARTICLE Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern Tetsuro Sawata, Masashi Bando, Masayuki Nakayama, Naoko Mato, Hideaki Yamasawa
More informationIdiopathic pulmonary fibrosis (IPF), also referred to as
Operation for Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis: Surgical Contraindication? Toshio Fujimoto, MD, Tsuyoshi Okazaki, MD, Tadashi Matsukura, MD, Takeshi Hanawa, MD, Naoki Yamashita,
More informationDescription. Section: Medicine Effective Date: October 15, 2014 Subsection: Medicine Original Policy Date: December 7, 2011 Subject:
Page: 1 of 9 Last Review Status/Date: September 2014 Description Lung volume reduction surgery (LVRS) is proposed as a treatment option for patients with severe emphysema who have failed optimal medical
More informationPulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
More informationSubpleural Honeycombing on High Resolution Computed Tomography is Risk Factor for Fatal Pneumonitis
Subpleural Honeycombing on High Resolution Computed Tomography is Risk Factor for Fatal Pneumonitis Hiroyuki Ito, MD, Haruhiko Nakayama, MD, Masahiro Tsuboi, MD, MD, Yoichi Kameda, MD, Tomoyuki Yokose,
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationclinical investigations in critical care The Role of Open-Lung Biopsy in ARDS*
clinical investigations in critical care The Role of Open-Lung Biopsy in ARDS* Sanjay R. Patel, MD; Dimitri Karmpaliotis, MD; Najib T. Ayas, MD; Eugene J. Mark, MD; John Wain, MD, FCCP; B. Taylor Thompson,
More informationThe Effect of Tidal Volume on Pulmonary Complications following Minimally Invasive Esophagectomy: A Randomized and Controlled Study
The Effect of Tidal Volume on Pulmonary Complications following Minimally Invasive Esophagectomy: A Randomized and Controlled Study Yaxing Shen, MD, Ming Zhong, MD, Lijie Tan, MD Zhongshan Hospital,Fudan
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationChanges in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation
Eur Respir J 2007; 29: 453 461 DOI: 10.1183/09031936.00015506 CopyrightßERS Journals Ltd 2007 Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after
More informationHYPERSENSITIVITY PNEUMONITIS
HYPERSENSITIVITY PNEUMONITIS A preventable fibrosis MOSAVIR ANSARIE MB., FCCP INTERSTITIAL LUNG DISEASES A heterogeneous group of non infectious, non malignant diffuse parenchymal disorders of the lower
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationAuthor s Accepted Manuscript
Author s Accepted Manuscript Low levels of physical activity predict worse survival to lung transplantation and poor early postoperative outcomesphysical activity level in lung transplantation James R.
More informationFariba Rezaeetalab Associate Professor,Pulmonologist
Fariba Rezaeetalab Associate Professor,Pulmonologist rezaitalabf@mums.ac.ir Patient related risk factors Procedure related risk factors Preoperative risk assessment Risk reduction strategies Age Obesity
More informationAcute Exacerbation of Usual Interstitial Pneumonia After Resection of Lung Cancer
Acute Exacerbation of Usual Interstitial Pneumonia After Resection of Lung Cancer Hiroaki Sugiura, MD, Atsuya Takeda, MD, PhD, Toshiko Hoshi, MD, PhD, Yoshinori Kawabata, MD, Koichi Sayama, MD, PhD, Masahiro
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationThe Diagnostic Yield of Open Lung Biopsy in relation to clinical and radiological features in Patients with Suspected Interstitial Lung Disease
Original Article The Diagnostic Yield of Open Lung Biopsy in relation to clinical and radiological features in Patients with Suspected Interstitial Lung Disease * Qasim M. Sultan** Abdulrasool N. Nassr***
More informationPulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Eur Respir J 2007; 30: 715 721 DOI: 10.1183/09031936.00107206 CopyrightßERS Journals Ltd 2007 Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant A.F. Shorr*, J.L. Wainright
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationINVITED REVIEW SERIES: PULMONARY FIBROSIS SERIES EDITORS: MARTIN KOLB AND GERARD COX
INVITED REVIEW SERIES: PULMONARY FIBROSIS SERIES EDITORS: MARTIN KOLB AND GERARD COX Diagnosing fibrotic lung disease: When is high-resolution computed tomography sufficient to make a diagnosis of idiopathic
More informationPrapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital
Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled
More informationFollicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients
Respiratory Medicine (2008) 102, 307 312 Follicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients Michelle R. Aerni a, Robert Vassallo a,, Jeffrey L. Myers b, Rebecca M.
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationCombined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationA 72-year-old male with worsening interstitial infiltrates and respiratory failure
A 72-year-old male with worsening interstitial infiltrates and respiratory failure Case report On November 24, 2004, a 72-year-old male was admitted to the medical intensive care unit (ICU) with a history
More informationOutcome of the Surgical Treatment of Bullous Lung Disease: A Prospective Study
Original Article 2012 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran ISSN: 1735-0344 TANAFFOS Outcome of the Surgical Treatment of Bullous Lung Disease: A Prospective Study
More informationClinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2013; 30; 103-112 Mattioli 1885 Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationBronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias
Respiratory Medicine (2007) 101, 655 660 Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Yon Ju Ryu a, Man Pyo Chung b,, Joungho Han c, Tae Sung Kim d, Kyung Soo Lee d, Eun-Mi Chun
More informationParenchymal air leak is a frequent complication after. Pleural Tent After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect
Pleural After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect Alessandro Brunelli, MD, Majed Al Refai, MD, Marco Monteverde, MD, Alessandro Borri, MD, Michele Salati, MD, Armando
More informationThe role of Pulmonary function Testing In Interstitial lung disease in infants. [ ipft in child ]
The role of Pulmonary function Testing In Interstitial lung disease in infants [ ipft in child ] Introduction Managing infants with diffuse lung disease (DLD) suspected to have interstitial lung disease
More informationBronchoscopic lung cryobiopsy increases diagnostic confidence. in the multidisciplinary diagnosis of idiopathic pulmonary
Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Sara Tomassetti, Athol U Wells, Ulrich Costabel, Alberto Cavazza, Thomas
More informationPrognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationCareful histopathological evaluation has shown the traditionally clinical diagnosis of
Demystifying Idiopathic Interstitial Pneumonia Harold R. Collard, MD; Talmadge E. King, Jr, MD REVIEW ARTICLE Careful histopathological evaluation has shown the traditionally clinical diagnosis of idiopathic
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationSCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More informationIdiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping
Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping K. R. Flaherty Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor,
More informationNew respiratory symptoms and lung imaging findings in a woman with polymyositis
Maria Bolaki 1, Konstantinos Karagiannis 1, George Bertsias 2, Ioanna Mitrouska 1, Nikolaos Tzanakis 1, Katerina M. Antoniou 1 kantoniou@uoc.gr 1 Dept of Thoracic Medicine, Heraklion University Hospital,
More informationAn earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationKey words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray
Nonspecific Interstitial Pneumonia Associated With Polymyositis and Dermatomyositis* Serial High-Resolution CT Findings and Functional Correlation Hiroaki Arakawa, MD; Hidehiro Yamada, MD; Yasuyuki Kurihara,
More information